Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry?
INDV and the Shift to Long-Acting Opioid Use Disorder Care in 2026
Is Indivior Stock a Buy After Higher 2026 Guidance?
INDV Stock: What Sublocade Growth Signals for 2026
5 Top-Ranked Efficient Stocks Beating Industry Peers on Key Metrics
What to Know About This Fund's $74.8 Million Indivior Sale
Why a Fund Made a $143 Million Bet on Indivior With Shares Up a Staggering 200%
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
Bears are Losing Control Over Indivior Pharmaceuticals Inc. (INDV), Here's Why It's a 'Buy' Now
Indivior to Participate in Upcoming Investor Conferences
Why One Fund Made a $23 Million Bet on This Addiction-Treatment Stock Amid a Staggering Rally
3 Best Momentum Stocks to Buy Now for Big Upside in May 2026
Indivior Pharmaceuticals Inc. (INDV) is a Great Momentum Stock: Should You Buy?
Indivior Pharmaceuticals Inc. (INDV) Upgraded to Strong Buy: Here's What You Should Know
Best Momentum Stock to Buy for May 5th
Indivior Announces $175 Million Accelerated Share Repurchase
Indivior Pharmaceuticals, Inc. (INDV) Q1 2026 Earnings Call Transcript
Indivior Pharmaceuticals Inc. (INDV) Q1 Earnings and Revenues Beat Estimates
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
Should Invesco Russell 2000 Dynamic Multifactor ETF (OMFS) Be on Your Investing Radar?
NVS SMA Drug Gets CHMP Backing, Malaria Drug Wins WHO Prequalification
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse
Indivior Pharmaceuticals Inc (INDV) Stock Down 5.5% but Still Overvalued -- GF Score: 72/100
How Much Upside is Left in Indivior Pharmaceuticals Inc. (INDV)? Wall Street Analysts Think 45.99%
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
Indivior: Still Attractive After FY25 Earnings Beat
3 Stocks With Strong Efficiency Metrics to Strengthen Your Portfolio
Indivior PLC (NASDAQ:INDV) Given Average Recommendation of “Buy” by Analysts
Down 12.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Indivior Pharmaceuticals Inc. (INDV)
National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering
Indivior Announces Proposed Convertible Senior Notes Offering
New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder
Intech Investment Management LLC Sells 20,478 Shares of Indivior PLC $INDV
Indivior PLC (NASDAQ:INDV) Receives $39.33 Consensus Target Price from Brokerages
Indivior Pharmaceuticals, Inc. (INDV) Q4 2025 Earnings Call Transcript
Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results
Indivior to Participate in Upcoming Investor Conferences
Indivior PLC (NASDAQ:INDV) Given Consensus Rating of “Moderate Buy” by Analysts
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
Indivior Announces Completion of Redomiciliation to the United States
Take the Zacks Approach to Beat the Markets: Indivior, FIGS & Ulta Beauty in Focus
4 Stocks Trading Near 52-Week High With Room to Rise Further
Indivior Provides Full-Year 2026 Financial Guidance and Business Update